Biotop-report 2011

11

B i o T O P i c s   4 2 _

B i o T O P   R e p o r t   2 0 1 1

PAREXEL International GmbH

PAREXEL International is a leading glob-

al biopharmaceutical services organiza-

tion, providing a broad range of knowl-

edge-based contract research, medical 

communications and consulting services 

to the worldwide pharmaceutical, bio-

technology and medical device indus-

tries. Committed to providing solutions 

that expedite time-to-market and 

peak-market penetration, PAREXEL has 

developed  significant  expertise  across 

the development and commercialization 

continuum, from drug development and 

regulatory consulting to clinical phar-

macology, clinical trials management, 

medical education and reimbursement. 

Perceptive Informatics, Inc., a subsidiary 

of PAREXEL, provides advanced technol-

ogy solutions, including medical imag-

ing, to facilitate the clinical develop-

ment process. Headquartered near Bos-

ton, Massachusetts, PAREXEL operates in 

71 locations throughout 52 countries 

around the world, and has approxi-

mately 10,380 employees. 

PAREXEL has a long-standing presence in 

Berlin, where over 1,500 employees are 

located.  Clients  can  benefit  from  state-

of-the-art technologies and equipment 

provided through PAREXEL’s medical 

imaging lab and Early Phase Units, 

which provide a safe, high-quality 

environment for early phase develop-

ment activities in a hospital setting. The 

PAREXEL Academy located in Berlin qual-

ifies  clinical  research  associates  and 

clinical data managers, and offers a 

course for a Bachelor of Science degree 

in Clinical Research, validated by a Brit-

ish university. 

Address 

PAREXEL International GmbH

Klinikum Westend · Haus 18

Spandauer Damm 130

14050 Berlin · Germany

Contact

Dr. Ulf Schneider

Senior Vice President and 

Chief Administrative Officer 

PAREXEL International

Phone [phone]

Fax 

[phone]

[e-mail]

www.parexel.com

ORGANOBALANCE GmbH

In Harmony with Nature 

ORGANOBALANCE is specializing in micro-

bial strain develop ment and screening. 

The company taps into the potential of 

beneficial  microorganisms,  known  as 

specific  probiotic  cultures,  to  compen-

sate  imbalances  in  the  microflora  and 

restore the microbial equilibrium. In 

close cooperation with leading indus try 

partners ORGANOBALANCE develops new 

biological products in the areas of nutri-

tion, cosmetics and preventive health 

care. In its development activities, the 

company draws on its own collection of 

microorganism strains suitable for food 

applications and its OASSYS

®

 screening 

systems.

Using innovative screening technologies 

and individually configured test designs, 

those  strains  of  microorganisms  are  fil-

tered  that  match  application-specific 

criteria. For suitable strains, fermenta-

tion and downstream processes are 

devel oped in a pilot scale production 

facility.

In a long-term partnership with leading 

international companies ORGANOBAL-

ANCE developed marketable strains of 

probiotic cultures that combat tooth 

decay, body odour and skin irritation on 

a natural basis. Own product develop-

ments are pursued. Examples of targets 

include gastrointestinal health and 

microorganisms with preservative effect.

ORGANOBALANCE has a comprehensive 

knowledge  and  experience  in  the  field 

of industrial biotechnology and devel-

ops strains by means of metabolic engi-

neering.

Address

ORGANOBALANCE GmbH

Gustav-Meyer-Allee 25

13355 Berlin · Germany

Contact

Dr. Christine Lang · CEO

Phone  [phone]

Fax 

[phone]

[e-mail]

www.organobalance.com

---

12

B i o T O P i c s   4 2 _

B i o T O P   R e p o r t   2 0 1 1

Prof. Dr. Roland Lauster

Director of the Department of Medical Biotechnology 

and Managing Director of the Biotechnology Institute 

at Technische Universität Berlin

The term regenerative medicine denotes the development and 

application of innovative medical therapies using biomaterials, 

cells and hybrid organs. This rapidly expanding interdisciplinary 

research  field  combines  the  methods  of  clinical  medicine  (e. g. 

orthopaedics, surgery, intensive and transplantation medicine) 

with molecular and cell biology (genomics, proteomics, stem cell 

research), chemistry and biochemistry, pharmacology as well as 

the  engineering  and  materials  sciences  (biomaterials,  bioengi-

neering), bioinformatics, medical engineering and nanotech-

nology. Berlin Brandenburg has taken up the challenge to bring 

together these diverse research approaches in order to accelerate 

the development of new therapies.

Translational Research

The Berlin Brandenburg Center for Regenerative Therapies (BCRT) 

is a center for translational research of the German Federal Min-

istry of Education and Research, and a joint initiative of Europe’s 

largest university hospital, the Charité, and Germany’s largest 

research organization, the Helmholtz association. The program 

focuses on endogenous regenerative therapies and is putting 

particular emphasis on research and clinical programs related to 

musculoskeletal, cardiovascular and immunological applications, 

since these aspects of regenerative medicine are most advanced 

at the Charité and closest to clinical translation. These medical 

research fields are linked to overlapping platforms on basic, bio-

materials, and translational research. 

The BCRT is located in a newly reconstructed building at the Chari-

té Campus Virchow Clinic. It is host to 26 newly implemented 

research groups. 19 groups are funded by the German Ministry for 

Education and Research, four groups are funded by the Helmholtz 

Association and three by the Deutsche Forschungsgemeinschaft 

(DFG).

For the interdisciplinary training of young scientists in the field 

of regenerative medicine in 2008 the Berlin-Brandenburg School 

for Regenerative Therapies (BSRT) was established as a graduate 

school of the German Excellence Initiative. It offers outstanding 

training and research opportunities for doctoral researchers in the 

biological and engineering disciplines and for clinical scientists.

In 2010 the BCRT has been positively evaluated by the German 

Ministry for Education and Research and therefore secured fund-

ing for another four years.

Exploring the Regenerative Potential of the 

Human Body

Regenerative medicine is one of the research areas that have developed particularly fast 

in recent years. The capital region has been one of the pioneers in the field in the 1990s 

and has since built up important institutions, notably the Berlin Brandenburg Center for 

Regenerative  Therapies  (BCRT)  and  the  Regenerative  Medicine  Initiative  Berlin-Branden-

burg (RMIB).

The Report “Regenerative  Medizin in Berlin  

Brandenburg” (in German language) is available 

for download at www.rmib.de

1

Technologiereport Regenerative Medizin in Berlin-Brandenburg

Inhalt

Technologiereport

Regenerative Medizin 

in Berlin-Brandenburg

Chips Instead of Animals

»

In the coming years, we expect the legal environment to 

develop and generate strong demand for a reduction in 

animal experiments. Our Multi-Organ Bioreactor in chip for-

mat permits reducing the number of substances requiring 

animal testing significantly because all substances that prove 

toxic on the chip no longer need to be tested in animals.

---